AEON Biopharma Reports No Significant Variation in Q2 2025 Financials, Maintains Cash Runway Through Expected FDA Meeting
AEON Biopharma, Inc. released its financial results for the second quarter ending June 30, 2025. The company reported cash and cash equivalents totaling $8.4 million, which is projected to support its operating plan through the fourth quarter of 2025, including the planned Type 2a meeting with the FDA in the fourth quarter of 2025. AEON Biopharma is progressing toward significant biosimilar development milestones, with the anticipated completion of primary structure analysis and select functional analyses of ABP-450 in the third quarter of 2025. Additionally, the company plans to utilize the 351(k) biosimilar regulatory pathway, using BOTOX® as the reference product. AEON expects the Type 2a meeting with the FDA in the fourth quarter to provide clarity on the development path forward for ABP-450, aiming to enhance patient accessibility to therapeutic neurotoxins.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001837607-25-000065), on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.